# US 2022/0033401 A1 · Ampk activators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033401 A1
- Document ID: US20220033401A1
- Status: Published application
- Kind: A1
- Application number: 17/502,474
- Filed: 2021-10-15
- Published: 2022-02-03
- Earliest claimed: 2020-05-19
- Assignees: Kallyope, Inc.
- Applicants: Kallyope, Inc.
- Inventors: Iyassu SEBHAT; Shuwen HE; Ann WEBER; Nancy THORNBERRY; Lisa KRUG; Paul RICHARDS; Brett LAURING
- Web page: https://patentgrep.com/patent/US20220033401A1

## CPC

- C07D 471/04: Ortho-condensed systems
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/662: Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.

## Claims

### Claim 1

A compound of Formula (III):
or a pharmaceutically acceptable salt thereof, wherein:
R2 is halogen, —CN, C1-C4 alkyl, or C1-C4 fluoroalkyl;
G is —C(O)OR7, —P(O)(R8)OR7, —P(O)(OR7)2, or —S(O)2OR7;
each R7 is independently hydrogen or C1-C4 alkyl;
R8 is C1-C4 alkyl;
A is phenyl which is substituted with 1, 2, or 3 R12 groups;
each R12 is independently —CN, —OH, —OR13, —NR14R14, —C(═O)OR14, —C(═O)NR14R14, OSO2OR14, C1-C6 alkyl, C1-C6 fluoroalkyl, or monocyclic heteroaryl;
each R13 is independently C1-C6 alkyl; and
each R14 is independently hydrogen or C1-C6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R2 is —F, —Cl, or —CN.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R3 and R4 are each independently hydrogen or methyl.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
G is —C(O)OH, —P(O)(Me)OH, —P(O)(OEt)(OH), —P(O)(OH)2, or —S(O)2OH.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
G is —C(O)OH.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R2 is —Cl;
R3 and R4 are each hydrogen; and
G is —C(O)OH, —P(O)(Me)OH, —P(O)(OEt)(OH), or —P(O)(OH)2.

### Claim 7 (depends on 6)

The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein:
G is —C(O)OH.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
each R12 is independently —F, —Cl, —Br, —CN, —OH, —OMe, —NH2, —C(═O)OH, —C(═O)NH2, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2CH3, —CH2CH(CH3)2, —CH(CH3)(CH2CH3), —CH2CH2C(CH3)3, —CF3, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, triazolyl, or tetrazolyl.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
each R12 is independently —OH, —OSO2OH, —CH2CH2C(CH3)3, or triazolyl.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
A is phenyl which is substituted with a —OH group and is optionally substituted with one other group selected from —CH2CH2C(CH3)3 and triazolyl.

### Claim 11 (depends on 1)

The compound of claim 1, having the structure of Formula (IV):
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein:
R2 is —F, —Cl, or —CN;
R3 and R4 are each independently hydrogen or methyl; and
G is —C(O)OH, —P(O)(Me)OH, —P(O)(OEt)(OH), —P(O)(OH)2, or —S(O)2OH.

### Claim 13 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein:
G is —C(O)OH.

### Claim 14 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein:
R2 is —Cl;
R3 and R4 are each hydrogen; and
G is —C(O)OH, —P(O)(Me)OH, —P(O)(OEt)(OH), or —P(O)(OH)2.

### Claim 15 (depends on 14)

The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein:
G is —C(O)OH.

### Claim 16 (depends on 1)

The compound of claim 1, selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

### Claim 18 (depends on 1)

A method of treating an adenosine 5′-monophosphate-activated protein kinase (AMPK) associated condition or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof; wherein the condition or disorder is short bowel syndrome, intestinal failure, intestinal insufficiency, metabolic syndrome, obesity, type 2 diabetes, coronary artery disease, fatty liver, nonalcoholic steatohepatitis (NASH), cirrhosis, hepatic encephalopathy, fibrotic disorders including scleroderma, inflammatory bowel disease including Crohn's disease and ulcerative colitis, psoriasis, celiac disease, necrotizing enterocolitis, gastrointestinal injury resulting from toxic insults such as radiation or chemotherapy, environmental enteric dysfunction, allergy including food allergy, celiac sprue, and childhood allergy, irritable bowel syndrome, spontaneous bacterial peritonitis, ischemic colitis, sclerosing cholangitis, Alzheimer's disease, Parkinson's disease, colorectal cancer, depression, autism, or a combination thereof.

### Claim 19 (depends on 1)

A method of treating gastrointestinal injury resulting from toxic insult, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the toxic insult is from radiation, chemotherapy, or a combination thereof.
